Gründer G, Brand M, Mertens L, Jungaberle H, Kärtner L, Scharf DJ, Spangemacher M, Wolff M. Treatment with psychedelics is psychotherapy: beyond reductionism. Lancet Psychiatry. 2024 11(3):231-236. Epub 2023 Dec 12.
Hart XM, Spangemacher M, Defert J, Uchida H, Gründer G. Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants. Ther Drug Monit. 2024 46(2):155-169.
Hart XM, Spangemacher M, Uchida H, Gründer G. Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics. Ther Drug Monit. 2024 46(1):16-32. Epub 2023 Nov 27.
Pedraz-Petrozzi B, Insan S, Spangemacher M, Reinwald J, Lamadé EK, Gilles M, Deuschle M, Sartorius A. Association between rTMS-induced changes in inflammatory markers and improvement in psychiatric diseases: a systematic review. Ann Gen Psychiatry. 2024 23(1):31.
Pedraz-Petrozzi B, Spangemacher M, Deicher A, Drews L, Defert J, Silva-Colmenero AY, Wein P, Riedinger E, Gründer G, Gilles M, Sartorius A, Reinwald JR. Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study. Front Psychiatry. 2024 15:1415505.
Spangemacher M, Hart X, Saalfrank E, Gründer G, Reinwald J, Sartorius A. Elevation of Alpha-1 Acid Glycoprotein During Acute Infection Increases Clozapine Levels Without Signs of Intoxication. J Clin Psychopharmacol. 2024 44(1):60-63.
Spangemacher M, Mertens L, Färber LV, Jungaberle A, Jungaberle H, Gründer G. Psilocybin as a Disease-Modifying Drug—a Salutogenic Approach in Psychiatry. Dtsch Arztebl Int. 2024 121(26):868-874. Epub 2024 Dec 27.